A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Inclusion Criteria:
Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria
Part 1 - Known 17p deletion status (wildtype or deleted). Part 2 - Must have deletion of 17p as determined by FISH testing
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Adequate organ function
Exclusion Criteria:
Part 2: participants must be treatment naïve
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Anaheim, California 92801, United States
714-999-1465
Palo Alto, California 94305, United States
San Marcos, California 92069, United States
Saint Augustine, Florida 32086, United States
New Orleans, Louisiana 70112, United States
Spokane, Washington 99218, United States
Ciudad Autónoma de Buenos Aire, C1426ANZ, Argentina
+54 9 11 4051-0781
Botucatu, 18618-687, Brazil
Santo André, 09060-650, Brazil
Viña del Mar, 2520000, Chile
Changsha, 410011, China
Hangzhou, 310009, China
Tianjin, 300020, China
Ürümqi, 830000, China
Wuhan, 430022, China
Yiwu, 322000, China
Rouen, 76038, France
Dortmund, 44309, Germany
Dresden, 01307, Germany
Alessandria, 15100, Italy
Lublin, 20-081, Poland
Seocho-Gu, 06591, South Korea
02-2228-6056
Chiayi County, 61363, Taiwan
+886-5-3621000 ext:2106
Faith, 34732, Turkey (Türkiye)
+90 533 575 90 96
562-693-4477
650-498-6000
727-216-1143
904-538-4488
561-366-4100
301-571-0019
406-238-6685
423-622-6212
(832) 553-3661 ext. 122
804-287-3000
509-462-2273
+54 (342) 4055449
+3216346880
+32 3 760 2985
+55 14 3880-1663
55 19 3521-8630
+55 (45) 9 9135 1056
(41) 9998-46033
555421034130
+55 51 33072943
16 98112-6986
+55.11.4993-5491
+55 (17)3201-5000
551135056675
+55 11 4573-7631
55 11 22173766
418-525-4444 ext. 0
+56974316500
+86 13798032244
+8613802426709
86 13505716779
8613856007984
+86 13855147434
+86 13507711671
13651680209
(+420) 532 233 642
+420 777 846 836
(+420) 597 372 749
(+420) 377 103 722
(+420) 267 163 530
(+420)224962527
+33251446173
+33 2.43.43.29.59
+33(0)555 05 88 22
33 (0)4 92 03 10 35
+33 1 42 16 15 96
+33 4 78 86 43 07
+33 299 28 4291
+ 33 2 32 08 22 23
+33 2 47 47 37 12
+4935144950701
3652255196
050-8573679
39 0131 206440
+390543739100
39.02.26434797
+39 02 57489403
81120023812
+ 64 212 618 734
+48696476575
48585844357
+48 600 388 282
+48451077231
+48 784 25 76
+82-51-890-6407
82 2 2072 3079
+34 93 556 5647
+34 932746000
+34619249275
+34 91 3368637
+34 91 191 68 80
+34 (951) 976-957
913531920 ext. 7511
+34848428428
942 31 52 75
+34619848594
+34955013277
+886-4-7813-888#70290
+886-2-28970011
+90 532 256 6160
90 505 502 50 50
0117 3421121
01792 285301